Inhibition of PCAF by anacardic acid derivative leads to apoptosis and breaks resistance to DNA damage in BCR-ABL-expressing cells

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 5, 2013, Pages 762-767

  Kusio Kobialka, Monika ^a   Dudka Ruszkowska, Wioleta ^a   Ghizzoni, Massimo ^b   Dekker, Frank J ^b   Piwocka, Katarzyna ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Acetylation; Anacardic acid; Apoptosis; BCR ABL; P300 CBP associated factor (PCAF)

Indexed keywords

ANACARDIC ACID; BCR ABL PROTEIN; HISTONE ACETYLTRANSFERASE PCAF;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME INHIBITION; FLOW CYTOMETRY; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PROTEIN EXPRESSION;

ANACARDIC ACIDS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; P300-CBP TRANSCRIPTION FACTORS; STEM CELLS;

EID: 84880163405     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313050010     Document Type: Article

References (28)

1. Fullgrabe, J.; Kavanagh, E.; Joseph, B. Histone onco-modifications. Oncogene, 2011, 30, 3391-3403.
2. Dekker, F.J.; Haisma, H.J. Histone acetyl transferases as emerging drug targets. Drug Discov. Today, 2009, 14, 942-948.
3. Glozak, M. A; Sengupta, N.; Zhang, X.; Seto E. Acetylation and deacetylation of non-histone proteins. Gene, 2005, 363, 15-23.
4. Peterson, C.L.; Genome integrity: A HAT needs a chaperone. Curr. Biol., 2007, 17, R324-326.
5. Singh, B.N.; Zhang, G.; Hwa, Y.L.; Li, J.; Dowdy, S.C.; Jiang, S.W. Nonhistone protein acetylation as cancer therapy targets. Exp. Rev. Anticancer Ther., 2010, 10, 935-954.
6. Mithraprabhu, S.; Grigoriadis, G.; Khong, T.; Spencer, A. Deactylase inhibition in myeloproliferative neoplasms. Invest. New Drug, 2010, 28, Suppl 1, S50-57.
7. Lee, S.M.; Bae, J.H.; Kim, M.J.; Lee, H.S.; Lee, M.K.; Chung, B.S.; Kim, D.W.; Kang, C.D.; Kim, S.H. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. J. Pharmacol. Exp. Ther., 2007, 322, 1084-1092.
8. Khan, O.; La Thangue, N.B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell. Biol., 2012, 90(1), 85-94.
9. Petrella, A.; Fontanella, B.; Carratu, A.; Bizzarro, V.; Rodriquez, M.; Parente L. Histone deacetylase inhibitors in the treatment of hematological malignancies. Mini Rev. Med. Chem., 2011, 11, 519-527.
10. Tanji, N.; Ozawa, A.; Kikugawa, T.; Miura, N.; Sasaki, T.; Azuma, K.; Yokoyama, M. Potential of histone deacetylase inhibitors for bladder cancer treatment. Expert Rev. Anticancer. Ther., 2011, 11, 959-965.
11. Marcu, M.G.; Jung, Y.J.; Lee, S.; Chung, E.J.; Lee, M.J.; Trepel, J.; Neckers, L. Curcumin is an inhibitor of p300 histone acetylatransferase. Med. Chem., 2006, 2, 169-174.
12. Wolanin, K.; Magalska, A.; Mosieniak, G.; Klinger, R.; McKenna, S.; Vejda, S.; Sikora, E.; Piwocka, K. Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells. Mol. Cancer Res., 2006, 4, 457-469.
13. Kusio-Kobialka, M.; Wolanin, K.; Podszywalow-Bartnicka, P.; Sikora E.; Skowronek, K.; McKenna, S.L.; Ghizzoni, M.; Dekker, F.J.; Piwocka, K. Increased acetylation of lysine 317/320 of p53 caused by BCR-ABL protects from cytoplasmic translocation of p53 and mitochondria-dependent apoptosis in response to DNA damage. Apoptosis, 2012, 17, 950-963.
14. Ghizzoni, M.; Boltjes, A.; Graaf, C.; Haisma, H.J.; Dekker, F.J. Improved inhibition of the histone acetyltransferase PCAF by an anacardic acid derivative. Bioorg. Med. Chem., 2010, 18, 5826-5834.
15. Dekker, F.J.; Ghizzoni, M.; van der Meer, N.; Wisastra, R.; Haisma, H.J. Inhibition of the PCAF histone acetyl transferase and cell proliferation by isothiazolones. Bioorg. Med. Chem., 2009, 17, 460-466.
16. Keeshan, K.; Mills, K.I.; Cotter, T.G.; McKenna, S.L. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia, 2001, 15, 1823-1833.
17. Piwocka, K.; Vejda, S.; Cotter, T.G.; O'Sullivan, G.C.; McKenna, S.L. Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calciumdependent apoptotic signaling. Blood, 2006, 107, 4003-4010.
18. Schiltz, R.L.; Mizzen, C.A.; Vassilev, A.; Cook, R.G.; Allis, C.D.; Nakatani, Y. Overlapping but distinct patterns of histone acetylation by the human coactivators p300 and PCAF within nucleosomal substrates. J. Biol. Chem., 2009, 274, 1189-1192.
19. Piaz, F.D.; Vassallo, A.; Rubio, O.C.; Castellano, S.; Sbardella, G.; De Tommasi, N. Chemical biology of histone acetyltransferase natural compounds modulators. Mol. Divers, 2011, 15, 401-416.
20. Ge, X.; Jin, Q.; Zhang, F.; Yan, T.; Zhai, Q. PCAF acetylates {beta}-catenin and improves its stability. Mol. Biol. Cell., 2009, 20, 419-427.
21. Hirano, G.; Izumi, H.; Kidani, A.; Yasuniwa, Y.; Han, B.; Kusaba, H.; Akashi, K.; Kuwano, M.; Kohno, K. Enhanced expression of PCAF endows apoptosis resistance in cisplatin-resistant cells. Mol. Cancer Res., 2010, 8, 864-872.
22. Falinski, R.; Nieborowska-Skorska, M.; Skorski, T. BCR-ABL1 kinase facilitates localization of acetylated histones 3 and 4 on DNA double-strand breaks. Leuk. Res., 2011, 36(2), 241-244.
23. Howe, L.; Auston, D.; Grant, P.; John, S.; Cook, R.G.; Workman, J.L.; Pillus, L. Histone H3 specific acetyltransferases are essential for cell cycle progression. Genes Dev., 2001, 15, 3144-3154.
24. Stimson, L.; Rowlands, M.G.; Newbatt, Y.M.; Smith, N.F.; Raynaud, F.I.; Rogers, P.; Bavetsias, V.; Gorsuch, S.; Jarman M.; Bannister, A.; Kouzarides, T.; McDonald, E.; Workman, P.; Aherne, G.W. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol. Cancer Ther., 2005, 4, 1521-1532.
25. Mateo, F.; Vidal-Laliena, M.; Canela, N.; Zecchin, A.; Martinez-Balbas, M.; Agell, N.; Giacca, M.; Pujol, M.J.; Bachs, O. The transcriptional co-activator PCAF regulates cdk2 activity. Nucleic Acids Res., 2009, 37, 7072-7084.
26. Mateo, F.; Vidal-Laliena, M.; Pujol, M.J.; Bachs, O. Acetylation of cyclin A: a new cell cycle regulatory mechanism. Biochem. Soc. Trans., 2010, 38, 83-86.
27. Liu, L.; Scolnick, D.M.; Trievel, R.C.; Zhang, H.B.; Marmorstein, R.; Halazonetis, T.D.; Berger, S.L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol., 1999, 19, 1202-1209.
28. Sakaguchi, K.; Herrera, J.E.; Saito, S.; Miki, T.; Bustin, M.; Vassilev, A.; Anderson, C.W.; Apella, E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev., 1998, 12, 2831-2841.